Currently enrolling studies:
Neurodegenerative Disorders Cerebrospinal Fluid (CSF) Biorepository
- This study is investigating potential biomarkers for Parkinsonian disorders by collecting cerebrospinal fluid, the fluid that the brain sits in. Samples may also be used for future research.
- The study will collect clinical information and cerebrospinal fluid sample from individuals with any type of Parkinsonian disorder. Non-UCSD patients will first need to be seen at UCSD to confirm the diagnosis and medical history. Participation will include one study visit to complete a lumbar puncture.
Non-Invasive Continuous Ultrasonic Blood Pressure Monitoring
- This research study is evaluating the use of continuous blood pressure monitor ultrasonic patch to learn more about orthostatic hypotension. The study is recruiting healthy volunteers and individuals with Hypotension, Prehypertension and Stage 1 or 2 hypertension.
Non-Invasive Neurophysiological Characterization of Movement Disorders
- The goal of this study is to learn more about movement disorders including tremor, Parkinson's disease, dystonia, myoclonus, neuromyotonia, ataxia, functional movement disorders, and others using non-invasive neurophysiologic techniques and clinical evaluation.
- The study also aims to teach neurologists in-training as well as other trainees in neurophysiological techniques used in the diagnosis of movement disorders.
PDGENE - Parkinson's Foundation: PDGeneration: Mapping the Future of PD
- This study is focused on assessing the impact, feasibility and participant satisfaction of offering genetic counseling as part of clinical care for people with Parkinson's Disease.
- The study will collect clinical information and blood sample from individuals with Parkinson’s disease at one visit.
WMMS: Development of a Wearable Multi-Modal Monitoring System (WMMS) to determine causes of Falls in Parkinson's Disease and Atypical Parkinsonian Disorders
- The aim of this study is to develop and test clinical applications of a wearable device that will continuously record multiple physiologic parameters such as blood pressure, heart rate, motion, brain activity etc. in patient's real life settings.
- This study is recruiting participants with Parkinson's disease and Atypical Parkinsonian Disorders such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), Corticobasal Degeneration (CBD) and Multiple System Atrophy (MSA).
PADOVA-BN42358: A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter study to evaluate the efficacy and safety of intravenous Parsinezumab in participants with Early Parkinson's Disease
- The study will evaluate the efficacy, safety and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's Disease (PD) over the course of 76 weeks with infusions occurring every 4 weeks.
- Expected to start enrollment in late Spring/early Summer 2021.
Real-Time Microneedle Sensor Monitoring of Levodopa Levels in Parkinson's disease
- The project aims to develop a continuous, minimally invasive microneedle device called the "Levodopameter" which is designed to continuously measure levodopa levels in real time, with the future goals of identifying an individualized treatment regimen for Parkinson's disease patients to improve disease management.
- This study is recruiting participants with Parkinson's disease as well as healthy volunteers.
- More information about this study can be found here: https://www.clinicaltrials.gov/ct2/show/NCT04735627
wAid: Web-based Automated Imaging Differentiation of Parkinson
- The study will test the performance of non-invasive biomarker to assess whether diffusion-weighted MRI can distinguish between parkinsonian syndromes using an automated imaging approach.
- Enrollment will start late spring
ORCHESTRA/UCBPD0053: A double-blind, placebo-controlled, randomized, 18-month Phase 2A study of oral UCB0599 in study participants with early Parkinson's Disease
- The principal aim of the study is to evaluate the safety, efficacy, tolerability and pharmacokinetics of oral drug UCB0599.
- Individuals looking to participate in the study must have never taken anti-Parkinsonian medications for an extended period of time (short courses for diagnostic purposes is allowed).
- Diagnosed with in 2 years and between the ages of 40-70 years old.
- Expected enrollment will start in late spring.
For further information about this and other studies, please contact Aishwarya Niraula by email email@example.com or phone 858-246-3190.